Tenax Therapeutics, Inc. (TENX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
ONE Copley Parkway
Chapel Hill, NC 27560
United States of America (the)
Phone
919 855 2100
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
April 04, 1994
| Name | Title | Pay | Year Born |
| Christopher T. Giordano | Chief Executive Officer, President & Director | 813,633 | 1975 |
| Thomas A. McGauley | Principal Financial Officer & Principal Accounting Officer | 475,498 | 1973 |
| Stuart Rich | Chief Medical Officer & Director | 490,217 | 1950 |
| Timothy G. Healey | Chief Commercial Officer | 0 | 1966 |
| Douglas Hay | Executive Vice President of Regulatory Affairs | 0 | N/A |
| So-Young Kim | Executive Vice President of Clinical Development & Strategy | 0 | N/A |
| Doug Randall | Chief Business Officer | 0 | N/A |
| Thomas R. Staab | Chief Financial Officer | 0 | 1968 |
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.